Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men aged 18 or older who have been diagnosed with prostate cancer (confirmed by tissue biopsy) and had their prostate surgically removed to treat localised cancer within the past 10 years, and whose PSA level after surgery is 0.05 ng/mL or higher (either remaining elevated or rising)
- People whose prostate removal surgery took place at least 4 months before enrolling, and where the cancer had not spread to nearby lymph nodes at the time of surgery
- People with a general health and activity level rated as reasonably functional (confirm with trial site for exact rating)
- People who have had recent imaging (within the past 90 days) showing no clear signs that the cancer has spread to other parts of the body — the type of scan required depends on the PSA level at the time of registration (confirm specific imaging requirements with trial site)
- Sexually active participants must agree to use adequate contraception throughout the study treatment period and for 60 days after it ends, and must inform their treating doctor immediately if a female partner becomes pregnant or suspects pregnancy during the study
- People who are able to understand and willing to sign a written consent form agreeing to take part
Who may not be able to join:
- People who have previously received hormone-blocking therapy (ADT) for more than 3 months, or anti-androgen medication for more than 30 days — shorter courses may be acceptable, but a minimum 30-day clearance period is required, along with confirmation that testosterone levels have returned above a certain threshold (confirm details with trial site)
- People currently using testosterone replacement therapy who are unwilling to stop it — stopping is required, and specific PSA and testosterone level checks must be met after at least 14 days off the therapy
- People who have previously had radiotherapy to the pelvic area
- People with serious uncontrolled health conditions, such as an active infection, heart failure, unstable chest pain, irregular heart rhythm, or significant mental health or personal circumstances that the trial doctors believe would make it difficult to follow the study requirements
- People with a history of bladder neck or urethral narrowing that has required a medical procedure to treat
- People who have or have had another cancer whose history or treatment could interfere with the safety or results of this study, in the opinion of the trial doctors
- People with active inflammatory bowel disease that regularly requires systemic medication or steroid-based treatments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Aurelie Garant, MD, University of Texas Southwestern Medical Center
Phone: 214-645-8525
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Freedom from failure
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.